Longeveron to Present at Biotech Showcase 2025
18. Dezember 2024 09:10 ET
|
Longeveron
Longeveron Chief Executive Officer Wa’el Hashad will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025.
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
17. Dezember 2024 09:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration with Eli Lilly and Company for the Transformative Bio-Hermes-002 Study
09. Dezember 2024 10:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This...
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
02. Dezember 2024 09:05 ET
|
Longeveron
Longeveron will participate in the Emerging Growth Virtual Conference with company presentation December 5th at 12:00pm ET.
Annovis to Host Year-End Investor Webcast on December 11, 2024
25. November 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased...
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
12. November 2024 16:05 ET
|
Longeveron
Longeveron reports 3Q24 financial results. Pivotal Phase 2b clinical trial in HLHS achieves 80% enrollment. Positive Phase 2 data for Alzheimer's disease.
Bridging Health Equity Gaps: Creyos Launches an Even More Accessible Patient Experience
05. November 2024 08:00 ET
|
Creyos
Toronto, Canada, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Creyos, a leader in cognitive and behavioral health assessment, has announced significant enhancements to its online platform to improve...
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
29. Oktober 2024 10:00 ET
|
Longeveron
Longeveron presents clinical data for stem cell therapy in Alzheimer's disease. Findings offer potential mechanistic and clinical insights.
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
29. Oktober 2024 07:48 ET
|
Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
Collaborative effort to conduct a study aimed at improving the diagnosis of Alzheimer’s and related dementias for everyone
28. Oktober 2024 10:00 ET
|
Global Alzheimer’s Platform Foundation®
Washington D.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These...